Forty-Third Report - COVID-19: Planning for a vaccine Part 1

The government response does not address the recommendation regarding an assessment of vaccine supply chain risks and a plan to address them.

The government response does not address the recommendation for BEIS to review its investment decisions, appointment processes, and the use of the Taskforce model.

The government's response is a non-sequitur, referring to HM Treasury's breach of capital expenditure rather than providing an assessment of vaccine deployment challenges and risks as requested.

The government agrees with the recommendation, stating it has already implemented it by publishing the Covid-19 Vaccine Delivery Plan and the COVID-19 Vaccine Uptake Plan, and provides clear daily and weekly data, including breakdowns by age, region, ethnicity, and cohort.

The government agrees with the recommendation and states it has already implemented it, detailing ongoing efforts in clear public communication, provision of information on NHS.UK and GOV.UK, sharing FAQs with partners, and establishing cross-government units to counter misinformation.

The government response refers to an unrelated PAC conclusion about BEIS's expenditure, completely failing to address the committee's introductory statement about the basis of its report.

The government response reiterates the committee's description of the Vaccines Taskforce's creation and purpose, and does not provide new information or address the committee's implicit query about retaining skills and expertise.

The government agrees with the committee's observations, stating BEIS has considered its decision-making and appointments processes, implemented improvements for robust decision-making, and will consider replicating these improvements and sharing lessons learned with other departments.

The government agrees with the implied recommendation on transparency and conflicts of interest, outlining process improvements for decision-making, expert appointments, and managing conflicts within the Taskforce, while committing to future consideration of replicating these improvements and reporting lessons learned by April 2021.

The government response is a verbatim, truncated repetition of the committee's conclusion, providing no further information on vaccine procurement prices or quantities.

The government response reiterates the committee's observation that the UK has more vaccine doses than likely needed if all work, but does not provide its own specific update or position.

The government response is a verbatim, truncated repetition of the committee's conclusion, offering no additional information on vaccine supply timetables.

The government response is a verbatim, truncated repetition of the committee's conclusion, providing no further details or updates on vaccine manufacturing capacity.

The government response is a verbatim, truncated repetition of the committee's conclusion, failing to engage with its content regarding vaccine rollout targets.

The provided government response is truncated and merely repeats the committee's observations about the vaccine roll-out without addressing them or offering any new information.

The government response is a verbatim, truncated repetition of the committee's conclusion, offering no specific updates on plans for an annual vaccination programme or response to changing vaccine information.

The government response is a verbatim, truncated repetition of the committee's conclusion, providing no new information on vaccine prioritisation decisions or advice.

The government response is a verbatim, truncated repetition of the committee's conclusion, failing to address the content or provide an update on vaccine prioritisation.

The government response reiterates the committee's observations about the differing logistical requirements for vaccine deployment based on their characteristics, without adding new information or committing to further action.

The government response reiterates the committee's conclusion about the estimated staffing needs for the vaccination program and the successful recruitment efforts, but provides no new information or specific government action.

The government response reiterates the committee's conclusion on NHSE&I's development of new vaccine delivery models and the importance of local oversight, but offers no new information or specific government action.

The government response reiterates the committee's concern about a 'stop-start' vaccination system and NHSE&I's confirmation of considering smooth distribution, but provides no new information or specific government action.

The government response reiterates the committee's conclusion regarding the disproportionate impact of COVID-19 on vulnerable groups and PHE's recognition of the issue, but does not provide its own specific response or update.

The government response reiterates the committee's observation and concern regarding the clarity of language used to describe vaccine progress, but does not provide its own specific response or planned actions.

The government accepts the committee's conclusion by reiterating that the 12-week gap between doses was based on independent JCVI advice to maximise the early impact of the vaccination programme.

The government accepts the conclusion, stating that Public Health England, in partnership with NHS England and Improvement, continues to develop insights into vaccine hesitancy using academic experts, behavioural scientists, regular polling, and qualitative research.

The government accepts the importance of convenience and trusted local sources for vaccine uptake and is working to provide choices for vaccination locations (GP practices, pharmacies, mass centres) and culturally sensitive messaging through local authorities and community leaders.

The government accepts the importance of public trust and clear communication, detailing its ongoing efforts to provide public information via NHS.UK and GOV.UK, sustained communications campaigns informed by polling, and cross-government work to counter myths and misinformation.

The government accepts the importance of clear communication and outlines ongoing efforts, including detailed public information on NHS.UK and GOV.UK, proactive communications campaigns based on polling, sharing information with community leaders, and cross-government work to counter misinformation.

The government accepts the need for clear communication, including FAQs, and details its ongoing efforts to provide public information via NHS.UK and GOV.UK, proactive communications campaigns, and the sharing of FAQs with partners and community leaders.

The government states it has worked closely with various bodies on clear public communication regarding vaccine development and rollout, maintaining proactive information campaigns to inform the public, address vaccine hesitancy, and tackle misinformation to prevent scams.